The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2020 | Lung cancer: actionable targets

Name: Lung cancer: actionable targets
Uploaded: 2020-01-31T00:00:00Z
Duration: 4 min 16 s
Description: Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, discusses actionable target in lung cancer, drawing on data from the ALTA-1L study (NCT02737501) at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Samreen Ahmed • 31 Jan 2020

BTOG 2020

Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Crizotinib

ALTA-1L

Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, discusses actionable target in lung cancer, drawing on data from the ALTA-1L study (NCT02737501) at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.